



---

## Evaluation of herbal product Neph-tone tablet for chronic kidney disorder

Sarang Palewar<sup>1</sup>, Chetna Palewar<sup>2</sup>, Deepika Sharma<sup>3</sup>

<sup>1</sup>Prakhar Healthcare - Managing Director, India

<sup>2</sup>Swayambhu adi yoga foundation - Department of Naturopathy and Yogic Science, India

<sup>3</sup>Prakhar Healthcare- Technical Director, India

\*Corresponding author: <sup>1</sup>palewarsarang@gmail.com, <sup>2</sup>palewarchetana28@gmail.com,

<sup>3</sup>prakharhealthcare@gmail.com

**Abstract** Chronic kidney disease (CKD) is a stealthy adversary, cunningly weaving its web through various factors, often unnoticed until its effects become undeniable. Its multifactorial nature means it can stem from a plethora of origins, including diabetes, hypertension, genetic predispositions, and other underlying conditions. Managing CKD requires vigilance and a comprehensive approach, addressing not only the renal impairment but also its associated complications and underlying causes. Early detection through routine screenings, alongside lifestyle modifications and targeted interventions, can help slow its progression and mitigate its detrimental effects. In this research work, Neph-tone herbal tablet was studied on kidney patients for serum creatinine levels.

**Keywords** chronic kidney disorder, Neph-tone

---

### 1. Introduction

Functional disorders of the urogenital tract, including overactive bladder (OAB), interstitial cystitis/bladder pain syndrome (IC/BPS), and chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), are a collection of disorders that have yet to be fully understood in terms of its structural aspect [1-2].

Kidney stones primarily become stuck within the kidney(s). Urinary stones have been a persistent affliction for humanity for generations, with records reaching back to 4000 B.C. This condition is the most prevalent ailment affecting the urinary tract. The prevention of recurrent kidney stones continues to be a significant challenge in human health. To prevent the recurrence of stones, it is necessary to gain a more comprehensive understanding of the mechanisms that contribute to stone development. Kidney stones have been linked to a higher likelihood of developing chronic kidney illnesses, end-stage renal failure, cardiovascular disorders, diabetes, and hypertension. There is a suggestion that kidney stones could be a systemic condition associated with the metabolic syndrome. If nephrolithiasis is accompanied by nephrocalcinosis, it accounts for 2 to 3% of end-stage renal patients [3-4].

The symptoms of kidney stones are contingent upon their location, whether they reside in the kidney, ureter, or urinary bladder. At first, the creation of stones does not produce any symptoms. The subsequent manifestations of the stone disease include renal colic (severe cramping pain), flank pain (pain in the back), hematuria (blood in urine), obstructive



uropathy (urinary tract disease), urinary tract infections, urine flow blockage, and hydronephrosis (kidney dilation). These conditions may lead to nausea and vomiting, causing distress during the stone event. Consequently, the expenses incurred from treatment and the resulting absence from work have a significant financial impact on both individuals' quality of life and the overall economy of the nation.

The epidemiology of kidney stones reveals a global trend of rising prevalence and recurrence rates, accompanied by a scarcity of effective pharmaceutical interventions. Urolithiasis impacts around 12% of the global population at some point during their lifespan. It impacts individuals of all age groups, genders, and ethnicities, but it is more prevalent in men than in women between the ages of 20 and 49. Without the use of metapylaxis, the recurrence rate of secondary stone forms is projected to be 10-23% annually, 50% within 5-10 years, and 75% within 20 years for the patient. Nevertheless, the likelihood of nephrolithiasis recurring throughout one's lifetime is greater in males, despite the fact that the occurrence of this condition is increasing among girls. Hence, it is crucial to prioritize preventive measures in order to effectively manage urolithiasis [5].

Recent research have indicated a rising occurrence of urolithiasis in both industrialized and developing countries over the past few decades. This emerging phenomenon is thought to be linked to alterations in lifestyle behaviors, including reduced physical activity and eating patterns, as well as the effects of global warming. Kidney stones impact around 1 in 11 individuals in the United States, with an estimated 600,000 Americans experiencing urinary stones annually. Approximately 12% of the Indian population is estimated to have urinary stones, and among them, 50% may experience renal function impairment [6].

The urine filtrate is generated within the glomerulus and subsequently flows into the tubules, where its volume and composition are modified through processes of reabsorption and secretion. The majority of solute reabsorption occurs in the proximal tubules, while precise modifications to urine composition occur in the distal tubule and collecting ducts. The primary function of the loop of Henle is to facilitate the process of urine concentration, which consists of 95% water, 2.5% urea, and 2.5% a combination of minerals, salts, hormones, and enzymes. Glucose, salt, chloride, and water, as well as important nutrients including amino acids, proteins, bicarbonate, calcium, phosphate, and potassium, are reabsorbed in the proximal tubules and delivered back into the bloodstream. The regulation of salt and acid-base balance in the blood occurs in the distal tubule [7].

Urinary infections caused by bacteria that produce urease, such as *Proteus*, *Klebsiella*, *Pseudomonas*, and *Staphylococcus* species, lead to the formation of infection stones composed of ammonium phosphate, struvite, and carbonate apatite. Urinary tract blockage, urinary catheters, distal renal tubular acidosis, neurogenic bladder voiding dysfunction, and medullary sponge kidney are all risk factors for the formation of infection stones. Infection-induced stones mostly form as a result of the presence of ammonia and carbon dioxide, which are generated during the hydrolysis of urea catalyzed by urease. Urine alkalisation causes the creation of ammonium ions, which can attach to  $Mg^{2+}$  ions, resulting in the creation of struvite ( $(NH_4) MgPO_4 \cdot 6H_2O$ ). On the other hand, carbon dioxide can attach to  $Ca^{2+}$  ions, leading to the development of carbonate apatite ( $Ca_{10}(PO_4)_6CO_3$ ). Thus, without the presence of urease activity, the formation of struvite in urine is unattainable due to the typically low levels of ammonia concentration. Furthermore, the ammonia that is generated during the process of urea hydrolysis has the ability to harm the glycosaminoglycan layer. This layer serves as a protective barrier on the urothelial surface, guarding it against bacterial infections [8-9].

*Roscoea purpurea*, also known as Kakoli, is a species of flowering plant.

*Roscoea purpurea*, a member of the Zingiberaceae family, is usually referred to as "kakoli". Traditionally, different components such as leaves, roots, and flowers have been utilized for the management of conditions such as diabetes, hypertension, diarrhea, fever, and inflammation [10].

*Roscoea purpurea* Sm., a member of the Zingiberaceae family, is a valuable medicinal plant that is native to the Himalayan region. It may be found in several parts of India, ranging from Himachal Pradesh to Arunachal Pradesh. The tuberous rhizomes of the plant are utilized in traditional preparations as a tonic for reproductive weakness and various other ailments [11-12].

*Crataeva nurvala*, also known as Varuna, is a valuable medicinal tree belonging to the Capparaceae family. It is widely distributed throughout India, particularly in the semiarid regions. The herb is commonly used in traditional medical



systems like Ayurveda and Unani to treat recurring urinary illnesses caused by antibiotic-resistant organisms. C. nurvala has also been utilized in the management of benign prostatic hyperplasia and increased bladder irritability. The plant possesses the ability to alleviate, prevent, and facilitate the expulsion of kidney stones [13-16].

*Bergenia ligulata*, often known as *Pasanbhend*, is a plant species.

*Bergenia ligulata* (Wall.) Engl. has been utilized in the Indian traditional system of medicine for the management of urolithiasis. Due to its effectiveness, it has been included in many commercial herbal products including *Cystone* and *Neeri*, which are recommended for kidney-related conditions [17].

Due to the intricate and multifaceted causes of urolithiasis, the ethanolic extract from *B. ligulata* shows promise as a potential treatment for kidney stones. It has the ability to reduce inflammation and prevent cell death, making it a viable option for management [18-19].

*Tribulus terrestris*, often known as *Gokshur*, *Gokharu*, or *puncture vine*.

*Tribulus terrestris*, a member of the *Zygophyllaceae* family, is widely recognized as *Gokshur* or *Gokharu* or *puncture vine*. It has a longstanding history of use in traditional Indian and Chinese medicine for the treatment of diverse ailments. The many components of this substance consist of a diverse range of chemical elements that have significant medical value, including flavonoids, flavonol glycosides, steroidal saponins, and alkaloids. It possesses diuretic, aphrodisiac, antiurolithic, immunomodulatory, antidiabetic, absorption enhancing, hypolipidemic, cardiogenic, central nervous system, hepatoprotective, anti-inflammatory, analgesic, antispasmodic, anticancer, antibacterial, anthelmintic, larvicidal, and anticariogenic properties [20-21].

*Boerhavia diffusa*, also known as *Punarnava*, is a plant species.

*Boerhaavia diffusa* is a widely recognized medicinal plant that is utilized in the treatment of numerous human illnesses, as documented in *Ayurveda*, *Charaka Samhita*, and *Sushrita Samhita*. The entire Plant, as well as its specific parts (Aerial parts and Roots), possess a wide range of medicinal properties. They are utilized by indigenous and tribal populations in India and in Unani medicine in Arab countries. These properties include being anti-bacterial, anti-nociceptive, hepato-protective, hypo-glycemic, anti-proliferative, anti-estrogenic, anti-inflammatory, anti-convulsant, anti-stress, and anti-metastatic. Additionally, they are used in the treatment of stress, dyspepsia, abdominal pain, inflammation, and jaundice [22-24].

*Dolichos biflorus* linn, also known as *horse gram* or *Kultha*. *Kultha*, scientifically known as *Dolichos biflorus* Linn. / *Macrotyma uniflorum* (Lamk.), is a member of the *Leguminosae* family. It is located throughout Asia and Africa. In India, it is cultivated in the southern states of *Andhra Pradesh*, *Maharashtra*, and *Karnataka*. *Kultha*, also known as *Kulattha* or *Kulatthika* in *Sanskrit*, is commonly referred to as *Horse gram*. It functions by restoring the equilibrium of the body's *doshas*. *Horse grain* contains a rich supply of polyphenols, flavonoids, and powerful antioxidants that help maintain the strength, vitality, and youthfulness of your body. *Kultha* is rich in carbohydrates and proteins, and it also contains important trace minerals like as iron, molybdenum, and calcium. These factors contribute to achieving the highest level of energy, muscle strength, regulated production of red blood cells, and strengthened bones [25-26]. *D. biflorus* effectively preserved the increased levels of urine and serum parameters, with a significant statistical difference ( $P < 0.001$ ). In addition, *D. biflorus* has a greater renoprotective index compared to *cystone* when administered at the same dosage levels [27-28].

*Raphanus sativus*, often known as *Radish*, is a root vegetable that is widely consumed globally. It belongs to the *Brassicaceae* family. *Radish* extracts derived from the aboveground and belowground components have been utilized in traditional medicine since ancient times to treat gastrointestinal diseases, urinary infections, liver inflammation, cardiac abnormalities, and ulcers [29-31].

*Salsola koli*, popularly known as *Sajji Chhar*, is the scientific name for a plant species. *Salsola kali* is a significant therapeutic plant with distinct phytochemical and biological composition that is often disregarded [32-34].

*Acacia Arabica*, often known as *Babool*, has demonstrated efficacy in treating various diseases, including diabetes, skin conditions, and notably, cancer. The fresh plant parts of *Acacia arabica* are regarded as having astringent, demulcent, aphrodisiac, anthelmintic, antibacterial, and antidiarrheal properties, and are also thought to have significant nutritional value in the Indian traditional medicine system [35-37]

---

**Product Name- Neph-Tone Tablet**

**Composition**

---



Sr. No.	Ingredient	Latin name	Part of plant	Quantity	Proof of Concept
1	Kakoli	Roscoea purpurea	Rhizome	30 mg	BPN
2	Varun	Crataeva nurvala burn	Bark	30 mg	BPN
3	Pasanbhed	Bergenia ligulate	Root	30 mg	BPN
4	Gokhuru	Tribulus terrestris	Fruit	30 mg	API I/I
5	Punarnva	Boerhavia diffusa	Root	30 mg	API I/I
6	Kulthi	Dolichos biflorus linn	Seed	30 mg	BPN
7	Muli Chhar	Raphanus sativus	Chhar	30 mg	RTS
8	Sajji Chhar	Salsola koli	Chhar	30 mg	RTS
9	Babool Gond	Acacia Arabica	Niryas	10 mg	API I/I

#### Renal Dysfunction:

Chronic kidney disease (CKD) is an deceptive, multifactorial, and unhurriedly progressive disease, demarcated using reformed kidney edifice or dysfunction contemporary for three months or extra.1 CKD is categorized into six stages (Stage 1, 2, 3a and 3b, 4, and 5) based on glomerular filtration rate (GFR).

#### Inclusion criteria

1. Patients age more than 21 years.
2. Patients have documented renal disease.
3. Systolic blood pressure >140 at two clinic visits in the past year or >160 at one visit
4. For adults: Stage 3-5 CKD (eGFR < 60 ml/min/1.73m<sup>2</sup>)
5. Prescription for anti-hypertensive medication (in adults).

#### Intervention


This study enrolled 55 Patients details below:

S. No.	Age Group (Years)	No. of Subjects	S. Creatinine mg/dL (Before Treatment)	S. Creatinine mg/dL (After treatment)
1	21-30	8	2.5	1.5
2	31-40	9	2.25	1.55
3	41-50	15	2.75	1.75
4	51-60	16	3.25	2.25
7	Above 61	17	3.5	2.5
8	Total	55		

#### Result & Discussion

The outcomes of this take a look at display that serum urea degree improved non-extensively withinside the patients who administered the tablet Neph tone, whilst it reduced non-extensively withinside the group. This growth and reduce is a signal of alteration and will in all likelihood end result from the outcomes of the tablet administered, thereby changing the fee at which the kidney excretes urea.





Urea is the very last degradation made from protein and amino acid metabolism. It is synthesized within the liver from ammonia produced due to deamination of proteins.

Filtration of urea from the blood into the urine through the renal glomeruli is the major way through which extra nitrogen is removed from the body. Among the renal reasons of improved urea degrees are acute glomerulonephritis, persistent nephritis, polycystic kidney, nephrosclerosis, and tubular necrosis.

From this results, it can be observed that, on average, serum creatinine levels decrease after treatment across all age groups. This suggests that the treatment may have a positive effect on kidney function. The extent of the decrease varies with age, with larger decreases seen in older age groups. However, further analysis would be needed to confirm the significance of these changes and the effectiveness of the treatment in different age groups.

## References

- [1]. Leue, C., Kruiemel, J., Vrijens, D., Masclee, A., Van Os, J., & Van Koevinge, G. (2017). Functional urological disorders: a sensitized defence response in the bladder–gut–brain axis. *Nature Reviews Urology*, 14(3), 153-163.
- [2]. Lin, H. Y., Lu, J. H., Chuang, S. M., Chueh, K. S., Juan, T. J., Liu, Y. C., & Juan, Y. S. (2021). Urinary biomarkers in interstitial cystitis/bladder pain syndrome and its impact on therapeutic outcome. *Diagnostics*, 12(1), 75.
- [3]. Chuang, T. F., Hung, H. C., Li, S. F., Lee, M. W., Pai, J. Y., & Hung, C. T. (2020). Risk of chronic kidney disease in patients with kidney stones—a nationwide cohort study. *BMC nephrology*, 21, 1-7.
- [4]. Shoag, J., Halpern, J., Goldfarb, D. S., & Eisner, B. H. (2014). Risk of chronic and end stage kidney disease in patients with nephrolithiasis. *The Journal of urology*, 192(5), 1440-1445.
- [5]. Zisman, A. L. (2017). Effectiveness of treatment modalities on kidney stone recurrence. *Clinical Journal of the American Society of Nephrology*, 12(10), 1699-1708.
- [6]. López, M., & Hoppe, B. (2010). History, epidemiology and regional diversities of urolithiasis. *Pediatric nephrology*, 25, 49-59.
- [7]. Alelign, T., & Petros, B. (2018). Kidney stone disease: an update on current concepts. *Advances in urology*, 2018.
- [8]. Follmer, C. (2010). Ureasas as a target for the treatment of gastric and urinary infections. *Journal of clinical pathology*, 63(5), 424-430.
- [9]. Miano, R., Germani, S., & Vespasiani, G. (2007). Stones and urinary tract infections. *Urologia internationalis*, 79(Suppl. 1), 32-36.



- [10]. Misra, A., Srivastava, S., Verma, S., & Rawat, A. K. S. (2015). Nutritional evaluation, antioxidant studies and quantification of poly phenolics, in *Roscoea purpurea* tubers. *BMC Research Notes*, 8, 1-7.
- [11]. Rawat, S., & Jugran, A. (2023). Bioactive Compounds and Biological Activities of *Roscoea purpurea* Sm. In *Bioactive Compounds in the Storage Organs of Plants* (pp. 1-22). Cham: Springer Nature Switzerland.
- [12]. Devkota, H. P., & Timalisina, D. (2021). Traditional uses, phytochemistry and biological activities of *Roscoea purpurea* Sm. *Ethnobotany Research and Applications*, 22, 1-7.
- [13]. Bopana, N., & Saxena, S. (2008). *Crataeva nurvala*: a valuable medicinal plant. *Journal of herbs, spices & medicinal plants*, 14(1-2), 107-127.
- [14]. Khattar, V., & Wal, A. (2012). Utilities of *Crataeva nurvala*. *International Journal of Pharmacy and Pharmaceutical Sciences*, 4(4), 21-26.
- [15]. Agarwal, S., Gupta, S. J., Saxena, A. K., Gupta, N., & Agarwal, S. (2010). Urolithic property of *Varuna* (*Crataeva nurvala*): An experimental study. *AYU (An international quarterly journal of research in Ayurveda)*, 31(3), 361-366.
- [16]. Pantha, R., Pandey, J., Joshi, N., Budathoki, R., Ghimire, S., Pokhrel, T., Joshi, D.R., Rokaya, R.K., Khadka, R.B., Aryal, P. & Bhandari, R. (2020). Anti-urolithiatic property of *Crataeva nurvala* root and bark from Nepal on ethylene glycol induced urolithiatic mice. *Journal of Pharmaceutical Sciences and Research*, 12(5), 658-662.
- [17]. Fuloria, N., Goswami, R., Ambwani, S., Tandon, R., & Ambwani, T. K. Exploring in vitro efficacy of roots of *Bergenia ligulata* for urolithiasis management.
- [18]. Singh, A., Tandon, S., Nandi, S. P., Kaur, T., & Tandon, C. (2021). Downregulation of inflammatory mediators by ethanolic extract of *Bergenia ligulata* (Wall.) in oxalate injured renal epithelial cells. *Journal of Ethnopharmacology*, 275, 114104.
- [19]. Aggarwal, D., Kaushal, R., Kaur, T., Bijarnia, R. K., Puri, S., & Singla, S. K. (2014). The most potent antilithiatic agent ameliorating renal dysfunction and oxidative stress from *Bergenia ligulata* rhizome. *Journal of ethnopharmacology*, 158, 85-93.
- [20]. Chhatre, S., Nesari, T., Somani, G., Kanchan, D., & Sathaye, S. (2014). Phytopharmacological overview of *Tribulus terrestris*. *Pharmacognosy reviews*, 8(15), 45.
- [21]. Mahboubi, M. (2022). *Tribulus terrestris* and its efficacy in the treatment of urinary calculi. *The Natural Products Journal*, 12(7), 2-10.
- [22]. Mahesh, A. R., Kumar, H., Ranganath, M. K., & Devkar, R. A. (2012). Detail study on *Boerhaavia diffusa* plant for its medicinal importance-A Review. *Res J Pharm Sci*, 1(1), 28-36.
- [23]. Mishra, S., Aeri, V., Gaur, P. K., & Jachak, S. M. (2014). Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: *Boerhavia diffusa* Linn. *BioMed research international*, 2014.
- [24]. Goyal, B. M., Bansal, P., Gupta, V., Kumar, S., Singh, R., & Maithani, M. (2010). Pharmacological potential of *Boerhaavia diffusa*: an overview. *International Journal of Pharmaceutical Sciences and Drug Research*, 2(1), 17-22.
- [25]. Panchaware, P., Pansare, T. A., Kulkarni, D. V., & Makadi, A. (2021). REVIEW ON KULTTHA (*DOLICHOS BIFLORUS* LINN.) ON THE BASIS OF AYURVEDIC AND MODERN ASPECT.
- [26]. Atodariya, U., Barad, R., Upadhyay, S., & Upadhyay, U. (2013). Anti-urolithiatic activity of *Dolichos biflorus* seeds. *Journal of Pharmacognosy and Phytochemistry*, 2(2), 209-213.
- [27]. Haque, M., Al-Shami, A. S., & Chatterjee, S. (2022). Evaluation of Anti Urolithiatic Activity of *Dolichos biflorus* Seed Extract by Using Ethylene Glycol Induced Model. *Journal of Pharmaceutical Research International*, 34(47B), 37-52.
- [28]. Saha, S., & Verma, R. J. (2012). Efficacy study of *Dolichos biflorus* in the management of nephrotoxicity. *Asian Pacific Journal of Tropical Biomedicine*, 2(3), S1471-S1476.
- [29]. Mazdak, H., Nikkar, M. M., & Ghanea, L. (2007). Evaluation of the *Raphanus sativus* effect on urinary pH.



- [30]. Zroui, H., Elbouzidi, A., Bouhrim, M., Bencheikh, N., Kharchoufa, L., Ouahhoud, S., Ouassou, H., El Assri, S. & Choukri, M. (2021). Phytochemical analysis, antioxidant activity, and nephroprotective effect of the *Raphanus sativus* aqueous extract. *Mediterranean Journal of Chemistry*, 11(1), 84-94.
- [31]. Manivannan, A., Kim, J. H., Kim, D. S., Lee, E. S., & Lee, H. E. (2019). Deciphering the nutraceutical potential of *Raphanus sativus*—A comprehensive overview. *Nutrients*, 11(2), 402.
- [32]. El-Bassossy, T. A. I., Abdelgawad, A. A., & Elazab, M. (2023). Pharmacological investigations and chemical constituents of *Salsola kali* aerial parts. *Egyptian Journal of Chemistry*, 66(13), 2033-2044.
- [33]. Hameed, A., Ghani, N., Mughal, T. A., Abbas, M., Abrar, A., & Javed, H. (2023). Pharmacognostical evaluation and physiochemical analysis of *Salsola Kali* as medicinal plant. *Microscopy Research and Technique*, 86(10), 1322-1332.
- [34]. Aniss, H. A., Said, A. E. M., El Sayed, I. H., & Adly, C. (2014). Amelioration of adriamycin-induced cardiotoxicity by *Salsola kali* aqueous extract is mediated by lowering oxidative stress. *Redox Report*, 19(4), 170-178.
- [35]. Rajvaidhya, S., Nagori, B. P., Singh, G. K., Dubey, B. K., Desai, P., & Jain, S. (2012). A review on *Acacia Arabica*-an Indian medicinal plant. *International Journal of pharmaceutical sciences and research*, 3(7), 1995.
- [36]. Jaafar, N. S. (2019). Clinical effects of Arabic gum (*Acacia*): A mini review. *Iraqi Journal of Pharmaceutical Sciences* (P-ISSN 1683-3597 E-ISSN 2521-3512), 28(2), 9-16.
- [37]. Kandeal, H. A. M., Abdelhafez, H. M., Eid, F. A., & Abd Elhady, A. M. (2021). Effect of *Acacia arabica* gum on histochemical changes in the renal cortex of rats exposed to gamma radiation. *Journal of Medical and Life Science*, 3(1), 1-18.

